echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Biotech BAT6005 injection obtained clinical trial approval

    Biotech BAT6005 injection obtained clinical trial approval

    • Last Update: 2021-08-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On July 20, Biotech announced that it had recently received the "Clinical Trial Approval Notice" for the drug under development BAT6005 injection approved and issued by the State Food and Drug Administration


    BAT6005 is an anti-TIGIT monoclonal antibody of IgG1 subtype with normal Fc effect function developed by Biotech, which is intended to be developed for tumor treatment


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.